A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit <a rel="external noopener" href="https://mdpi-res.com/d_attachment/antioxidants/antioxidants-10-01703/article_deploy/antioxidants-10-01703.pdf?version=1635332857">the original URL</a>. The file type is <code>application/pdf</code>.
Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
<span title="2021-10-27">2021</span>
<i title="MDPI AG">
<a target="_blank" rel="noopener" href="https://fatcat.wiki/container/wmgngkdqend6ln62zly5podyxq" style="color: black;">Antioxidants</a>
</i>
Preserved Fulltext
Schizophrenia continues to be an illness with poor outcome. Most mechanistic changes occur many years before the first episode of schizophrenia; these are not reversible after the illness onset. A developmental mechanism that is still modifiable in adult life may center on intracortical glutathione (GSH). A large body of pre-clinical data has suggested the possibility of notable GSH-deficit in a subgroup of patients with schizophrenia. Nevertheless, studies of intracortical GSH are not
<span class="external-identifiers">
<a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.3390/antiox10111703">doi:10.3390/antiox10111703</a>
<a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/34829575">pmid:34829575</a>
<a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC8615159/">pmcid:PMC8615159</a>
<a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/rdpymsl6qrcklgtbm4otnqtuau">fatcat:rdpymsl6qrcklgtbm4otnqtuau</a>
</span>
more »
... e in this regard. In this review, we highlight the recent ultra-high field magnetic resonance spectroscopic studies linking GSH to critical outcome measures across various stages of schizophrenia. We discuss the methodological steps required to conclusively establish or refute the persistence of GSH-deficit subtype and clarify the role of the central antioxidant system in disrupting the brain structure and connectivity in the early stages of schizophrenia. We propose in-vivo GSH quantification for patient selection in forthcoming antioxidant trials in psychosis. This review offers directions for a promising non-dopaminergic early intervention approach in schizophrenia.
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20220430235244/https://mdpi-res.com/d_attachment/antioxidants/antioxidants-10-01703/article_deploy/antioxidants-10-01703.pdf?version=1635332857" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext">
<button class="ui simple right pointing dropdown compact black labeled icon button serp-button">
<i class="icon ia-icon"></i>
Web Archive
[PDF]
<div class="menu fulltext-thumbnail">
<img src="https://blobs.fatcat.wiki/thumbnail/pdf/a5/6e/a56ef58addef79a811a6cff5dfd82b1eea53b810.180px.jpg" alt="fulltext thumbnail" loading="lazy">
</div>
</button>
</a>
<a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.3390/antiox10111703">
<button class="ui left aligned compact blue labeled icon button serp-button">
<i class="unlock alternate icon" style="background-color: #fb971f;"></i>
mdpi.com
</button>
</a>
<a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615159" title="pubmed link">
<button class="ui compact blue labeled icon button serp-button">
<i class="file alternate outline icon"></i>
pubmed.gov
</button>
</a>